RESMED INC (RMD) Financial Ratio Screen

NYSE Healthcare United States USD 33531M
INSUFFICIENT / NOT IMPLEMENTED*
Automated financial screen · activity assessed separately
RESMED INC (RMD) needs additional financial data before the automated screen can be completed. One or more financial fields are missing; this is not a negative screening result.

Track RMD screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

RMD financial screening at a glance

INSUFFICIENT / NOT IMPLEMENTED*Financial ratios shown separately from business review — not a fatwa
Debt ratio
10.4%
Pass vs 30%
Cash ratio
14.8%
Pass vs 30%
Receivables + cash
26.9%
Pass vs 30%
Impermissible income
N/A
Not available vs 5%

Calculation date: 2026-08-31. Financial period used: June 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleMore financial data neededNo negative conclusion follows from missing data
FTSE/Yasaar-styleMore financial data neededNo negative conclusion follows from missing data
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodJune 2025Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Medical Instruments & Supplies) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from June 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 10.4%
/ 30%
14.8%
/ 30%
26.9%
/ 30%
N/A INSUFFICIENT / NOT IMPLEMENTED*
FTSE 10.4%
/ 33%
14.8%
/ 33%
26.9%
/ 50%
N/A INSUFFICIENT / NOT IMPLEMENTED*

Financial Highlights

P/E Ratio
22.2
Forward: 17.6
EPS
$10.48
Dividend Yield
114.0%
Payout: 23.0%
P/B Ratio
5.1
EV/EBITDA
15.7
EV: $32.9B
Beta
0.7
Low volatility
Current Ratio
3.1

Profitability

Gross Margin 61.6%
Operating Margin 30.9%
Net Margin 26.9%
Return on Equity (ROE) 24.3%
Return on Assets (ROA) 14.0%

Cash Flow & Balance Sheet

Operating Cash Flow$1.8B
Free Cash Flow$1.7B
Total Debt$852M
Debt-to-Equity12.5
Current Ratio3.1
Total Assets$8.2B

Price & Trading

Last Close$231.52
50-Day MA$207.74
200-Day MA$229.06
Avg Volume1.5M
Beta0.7
52-Week Range
$180.27
$286.91

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-08-25 for the financial period June 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About RESMED INC (RMD)

CEO
Mr. Michael J. Farrell BE, MBA, SM
Employees
11,370
Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Exchange
NYSE
Market Cap (listing currency)
USD 33531M
Currency
USD

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is RESMED INC (RMD) halal to invest in?

The current automated result is More financial data is needed. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is RESMED INC's debt ratio?

RESMED INC's debt ratio is 10.4% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are RESMED INC's key financial metrics?

RESMED INC has a market capitalization of USD 33531M in its listing currency, trailing P/E ratio of 22.2. The company maintains a gross margin of 61.6% and a net margin of 26.9%. Return on equity stands at 24.3%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: June 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.